SCHEMBL3532895

SCHEMBL3532895

CC(C)COC(=O)N1CCN(c2cncc(Cl)n2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.45
HPGD P15428 2/20 0.45
MEN1 O00255 2/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
HTR1A P08908 1/20 0.45
CYP2C9 P11712 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
CYP2C19 P33261 1/20 0.45
HSD17B10 Q99714 1/20 0.45
RAB9A P51151 1/20 0.44
KIT P10721 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
MAPT P10636 4/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10919038 0.89 RAB9A (0.55) KMT2AHPGDMEN1KDM4EALDH1A1
SCHEMBL1877788 0.79 PANK3 (0.58) KMT2AMEN1ALDH1A1CYP1A2KIT
SCHEMBL3532899 0.79 SMN1; SMN2 (0.47) KMT2AHPGDMEN1KDM4EALDH1A1
SCHEMBL1432444 0.79 CKS1B (0.56) KMT2AHPGDMEN1KDM4EALDH1A1
SCHEMBL3530997 0.78 KIT (0.43) KMT2AHPGDMEN1RAB9AKIT
SCHEMBL3808153 0.78 CKS1B (0.55) KMT2AHPGDMEN1KDM4EALDH1A1
SCHEMBL12991231 0.77 ALDH1A1 (0.41) KMT2AHPGDMEN1KDM4EALDH1A1
SCHEMBL11558817 0.77 MEN1 (0.55) KMT2AHPGDMEN1KDM4EALDH1A1
SCHEMBL3531390 0.77 TRPV1 (0.53) KITSMO
SCHEMBL12991312 0.76 ITGB2 (0.40) KMT2AHPGDMEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-7858786-B2 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCOROPATED (US) 2010-12-28 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093454-A1 Pyrimidines and pyrazines useful as modulators of ion channels KCNJ1, KCNJ2, KCNJ11 KMT2A 2851/4885HPGD 788/4885MEN1 3809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.